GlassScriptPhysician profile
Sheryl Dunn Newcomb
NPI 1326532003
$2,592.39
in general payments reported to CMS, 2019-2025
24 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $405 · 2023: $559 · 2024: $818 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $705.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.08 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $258.81 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $202.45 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $197.60 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $166.06 | 2022-2025 | Brilinta, Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $122.78 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $110.99 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $95.95 | 2023-2024 | Azure Xt Dr Mri Surescan, Linq II |
| Pfizer INC. | $77.37 | 2023-2025 | |
| Esperion Therapeutics, INC. | $62.85 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $53.04 | 2024 | Inpefa |
| Boston Scientific Corporation | $36.22 | 2025 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $33.87 | 2022-2024 | Optimizer |
| Janssen Pharmaceuticals, INC | $30.43 | 2024 | Xarelto |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.46 | 2023 | Jot Dx |
| Atricure, INC. | $19.19 | 2024 | |
| Scpharmaceuticals INC. | $19.18 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $18.92 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $16.65 | 2021 | |
| Cvrx, INC. | $16.38 | 2024 | Barostim Neo System |
| Novo Nordisk INC | $16.01 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $15.88 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.39 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl Newcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.